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Aim: to evaluate the presence of preservatives, dyes, 
sweeteners and flavouring substances in 73 pharmaceutical 
preparations of 35 medicines for oral administration, according 
to drug labeling information about the excipients. Methods: 
35 medications were selected, both over-the-counter and 
prescription durgs, marketed in Brazil. The sample included: 
analgesic/antipyretic, antimicrobial, mucoregulatory, cough 
and cold, decongestant, antihistamine, bronchodilator, 
corticosteroid, antiinflammatory and vitamin medications. We 
collected data on 73 preparations of these drugs, according 
to drug labeling information regarding preservatives, dyes, 
sweeteners and flavourings. Results: Methylparaben and 
propylparaben were the most common preservatives found 
(43% and 35.6% respectively). The most common sweeteners 
were: sucrose (sugar) (53.4%), sodium saccharin (38.3%) and 
sorbitol (36.9%). Twenty-one medicines (28,7%) contained 
two sweeteners. Colourless medicines predominated (43.8%), 
followed by those with sunset yellow dye (FD&C yellow 
no. 6) (15%). Five products (6.8%) contained more than one 
colour agent. Tartrazine (FD&C yellow no. 5) was present 
in seven preparations (9.5%). Fruit was the most common 
flavouring found (83%). Labelings of drugs which contained 
sugar frequently omitted its exact concentration (77%). Of 
the four labelings of medicines which contained aspartame, 
two did not warn patients regarding phenylketonuria. 
Conclusions: Omission and inacuracy of drug labeling 
information on pharmaceutical excipients may expose 
susceptible individuals to adverse reactions caused by 
preservatives and dyes. Complications of inadvertent intake of 
sugar-containing medicines by diabetics, or aspartame intake 
by patients with phenylketonuria may also occur.
Keywords: flavoring agents, pharmaceutical preservatives, 
pharmaceutic aids, parabens, drug labeling, tartrazine.
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INTRODUCTION
Excipient – or inactive constituent – is a substance 
without therapeutic power, used to guarantee stability, 
physicochemical and organoleptic properties of pharma-
ceutical products1.
Internal use medication excipients may be: preserva-
tives, dyes, flavorings, sweeteners, thickeners, emulsifiers, 
stabilizers or antioxidants. They keep medication free from 
micro-organisms and proper for consumption for longer 
time spans, besides making them tasty and thus favoring 
treatment compliance1,2.
The pharmaceutical industry uses thousands of 
excipients. A survey conducted in England found 3,816 
of these substances in a sample of 12,132 medications. 
Because of the excipients, the drugs analyzed presented 
710 different colors, 896 different flavors and 140 differ-
ent odors3.
Most excipients are used in low concentrations, thus 
adverse reactions are rare1. However, they may trigger 
undesirable effects due to intolerance – a non-immune 
mechanism which leads to anaphylactic reactions and 
idiosyncrasies – or allergies – immune mechanism which 
may result in immediate or late hypersensitivity4. In clini-
cal practice these reactions are commonly and mistakenly 
attributed to the medication active principle.
The pharmaceutical companies are obliged to dis-
criminate all inactive ingredients in medication inserts5,6. 
Notwithstanding, many health care providers do not read 
the insert or have no idea about excipients when prescrib-
ing drugs. 
Following we present the characteristics and adverse 
reactions of some of the most used excipients in pharma-
ceutical formulas for oral intake.
Preservatives
We highlight the parabens (methylparaben and 
propylparaben, for instance), used by the pharmaceuti-
cal, food and cosmetic industries since 1920. Parabens are 
large spectrum antimicrobial drugs, hydrosoluble, insipid, 
colorless and odorless7. With such characteristics they 
are broadly employed in the formulation of medications. 
Parabens concentrations vary, but hardly exceed 1%7.
Parabens are partially metabolized and becomes 
hydroxyparabenzoic acid, of which chemical structure 
is similar to that of acetylsalicylic acid. Although rare, 
parabens anaphylactic reactions may trigger urticaria and 
angioedema in individuals with salycilate intolerance7. The 
same symptoms may occur with the use of preservatives, 
such as benzoic acid and its salts (sodium, potassium and 
calcium benzoates)7.
Preservatives based on sulfur salts (calcium, po-
tassium and sodium metabisulfites, for instance) have 
also been considered as causes of persistent rhinitis and 
chronic urticaria8.
Dyes
Dyes may be organic or inorganic, natural or arti-
ficial. Examples of inorganic dyes are: Titanium dioxide 
and iron oxide9. Natural dyes are derived from plants or 
animals. Artificial dyes are made in the laboratory4.
Carmine red (# 4 red) is an example of a natural dye. 
It derives from carminic acid, extracted from the dry bod-
ies of the Dactylopius coccus (cochonilha) female insect. 
Some cases of occupational asthma and food allergy have 
been attributed to carmine, of which physiopathological 
mechanism is IgE mediated4,10.
Among artificial dyes we have the azo dyes – tar-
trazine yellow (FD&C # 5 yellow), dusk yellow (FD&C # 
6 yellow), Bordeaux S (FD&C # 2 amaranth or red) and 
Ponceau 4R (FD&C # 4 red), erythrosine (FD&C # 3 red) 
and indigocarmine (FD&C # 2 blue)4.
Tartrazine yellow is found in a number of medica-
tions, cosmetic agents and foodstuff. Its chemical structure 
is similar to that of benzoate, salycilate and indomethacin, 
thus the possibility of crossed allergic reactions with these 
substances5. Moreover, tartrazine may trigger hyperkinesia 
and eosinophylia in hyperactive patients5. The occurrence 
of non-thrombocytopenic purpura is rare; however it does 
mean that tartrazine is able to inhibit platelet aggrega-
tion, similar to salycilates, sodium benzoate and sodium 
metabissulfite11.
Hypersensitivity to tartrazine happens in 0.6 to 
2.9% of the population, with a higher incidence in atopic 
patients or those with intolerance to salycilates. The most 
common clinical aspects are: urticaria, bronchospasm, 
rhinitis and angioedema11. Despite the low incidence of 
tartrazine sensitivity in the general population, the drug 
companies are obliged, by force of law, to highlight a 
warning in the drug insert and package of the medications 
that have this dye12.
The dusk yellow dye (FD&C # 6) may also cause 
anaphylactoid reactions, angioedema, anaphylactic shock, 
vasculitis and purpura. There may be crossed reactions 
between dusk yellow, paracetamol, acetylsalicylic acid, 
sodium benzoate and other azo dyes5.
Sweeteners 
Liquid and chewable medications are usually very 
unpleasant to the taste, and sometimes it is necessary to 
combine different sweeteners in the same product in order 
to overcome this inconvenience2. The most used sweetener 
by the pharmaceutical industry are sucrose (sugar), its 
artificial surrogates (saccharin sodium, sodium cyclamate 
and aspartame)13 and sorbitol5.
Sucrose is of low cost, does not leave aftertaste and 
may act as preservative and antioxidant, it also enhances 
the viscosity of liquid medications. Its disadvantages are: 
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crystallization during medication storage – which may 
clog the container lid – and use forbidden to diabetic 
patients2.
Kulkarni et al. (1993)14 assessed the liquid pediatric 
presentations of 499 medications, including: antitussive 
drugs, antimicrobial drugs, analgesics, antivomiting and 
antiparasitic drugs. They reported that 82% of the liquid 
formulations had sugar in them, and this makes them for-
bidden to diabetic children and fosters dental cavities. 
People with lactose intolerance may present flatu-
lence and diarrhea if they take medications that harbor 
this suggar5.
Aspartame, sodium cyclamate and sodium saccharin 
may induce hypersensitivity reactions, which cause urti-
caria, pruritus and angioedema15. There is the possibility of 
a crossed allergic reaction between saccharin, aspartame 
and sulfonamides5.
Cyclamates may cause photosensitization, eczema 
and dermatitis. They are no longer used as sweeteners in 
the USA since 1970, by a determination of the FDA - Food 
and Drug Administration5, because of its carcinogenic 
potential seen in laboratory animals, although this rela-
tionship between cyclamate use and cancer developing 
in humans have never been proved16.
Aspartame may cause renal tubular acidosis when 
used in large quantities5. Its use is counterindicated in 
patients with phenylketonuria because it has phenylala-
nine.
Sorbitol may cause osmotic diarrhea – usually fol-
lowed by flatulence and abdominal pain; impairing the 
uptake of the medication active principle5.
Flavorings
These ingredients are used to enhance the flavor 
of medications. They usually are industry secrets, thus not 
specified in medicine inserts.
Flavorings may be natural (essential oils extracted 
from plants and fruit natural flavors) or artificial (aromatic 
alcohol, aldehydes, balms, phenols, terpenes, etc). Benzil 
acetate, for instance, is a medication component with arti-
ficial cherry, peach, apricot and strawberry flavors5.
Adverse reactions to flavorings are rare, since these 
chemical compounds are employed in minute concentra-
tions in medications5.
This study aimed at analyzing: a) the presence of 
preservatives, sweeteners, dyes and aromatizers in 73 drug 
preparations – liquid or in granules – of 35 oral use medi-
cations, and b) insert information about excipients.
METHODS
We selected 35 oral use medications available in 
the Brazilian market. The sample included: analgesic/
antipyretic, antimicrobial, mucolytic, antitussive, decon-
gestants, anti-histamine, bronchodilators. Steroids, anti-
inflammatory and vitamin supplements (Table 1). From 
June to September of 2004 we analyzed the inserts of 73 
presentations of these medications from different com-
mercial brands, prescription or over the counter drugs. For 
analysis purposes, both liquid and granulated presenta-
tions were chosen. 
Insert data were noted on the presence of preserva-
tives, sweeteners, dyes and aromatizers in the formulations. 
In cases of doubts on the insert information we called the 
Customer Care Service of the respective pharmaceutical 
companies.
RESULTS
Of the 73 pharmaceutical formulations analyzed, 31 
were oral drops or liquid solutions (42.5%), 26 were syrups 
(35.6%), 13 were oral suspensions (17.8%) and three were 
in granules (4.1%).
All inserts mentioned the formulation excipients in 
details, except for a carbocystein presentation in drops, 
sold over the counter. 
Preservatives
Table 2 lists insert information about the presence 
of preservatives in the medication formulas. The total 
adds to more than 100% because many of the drugs have 
more than one preservative. The most frequent ones were: 
methylparabenzene, found in 33 formulations (45.2%), 
propylparaben, in 26 formulations (35.6%), sodium benzo-
ate, in 24 presentations (32.8%) and sodium metabisulfite, 
in eight formulations (11%)
Sweeteners
The sweeteners used in the formulations studied 
were sucrose (sugar) in 39 drugs (53.4%), sodium saccharin 
in 28 (38.3%), sorbitol in 27 (36.9%), sodium cyclamate in 
19 (26%) and aspartame in four (5.4%).
Twenty one medications (28.7%) had two sweeten-
ers; seven (9.5%) had three sweeteners and three (4.1%) 
had four sweeteners. Of the 26 pharmaceutical formula-
tions in syrup-type, 18 (69.2%) had sugar in it. 
Among the inserts of 39 medications which had 
sugar in them, only nine (23%) specified its concentra-
tion, which varied from 0.349 g/ml (in a carbocystein 
cough syrup) to 0.72 g/ml (in an oral solution of sodium 
dipirone).
We contacted the Customer Care Service of a phar-
maceutical company to clarify the sugar concentration in 
two of their products and received the information request-
ed. According to the attendant, the sugar concentration in 
the medication is not mentioned in the insert “in order to 
prevent the competition to copy the compound”. 
The inserts of the medication containing sugar var-
ied as to the information given to diabetic patients. Two 
commercial brands of the sodium dipirone oral solution 
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Table 1. Groups of medications analyzed, active principles and respective number of formulations included in the study.
Group Active principles # of formulations
Analgesic/antipyretic
Sodium dipirone
ibuprofen
paracetamol
5
3
5
Anti-inflammatory
Benzydamine chloridrate
nimesulide
1
2
Anti-histaminic
Cetirizine chloridrate
Epinastine chloridrate
loratadine
desloratadine
ebastine
dexchlorpheniramine maleate
1
1
1
1
1
1
Antimicrobial
amoxicillin 600mg, potassium clavulanate 42.9mg
amoxicillin 50mg, sulbactam 50mg
azithromicin
monohydrated cephadroxyl 
monohydrated cefprozil 
trimethropin, sulphametoxazole
Sultamicillin tosilate
1
1
2
2
1
3
1
Antitussive
dropropizine 3
dropropizine, paracetamol, diphenydramine chloridrate, de pseudoephedrine chlori-
drate
2
levodropropizine 5
Bronchodilators
acebrophylin
bambuterol chloridrate
4
1
Steroids
prednisolone
dexchlorphenyramine maleate, betamethasone
3
1
Oral decongestants
bronpheniramine, phenylephrin
paracetamol, phenylephrin, chlorphenamine
loratadine, pseudoephedrine sulphate
azatadine maleate, pseudoephedrine sulphate
2
2
2
1
Mucolytic
carbocystein
ambroxol chloridrate
acethylcystein
Hedera helix dry stratum
6
3
1
1
Vitamin supplements
polyvitamins
Ascorbic acid
2
1
Total  73
alerted that the product should not be used by diabetic 
patients because it had sugar in it – they warned customers 
that the product was counter-indicated for diabetic patients, 
without specifying the reasons why. Three carbocystein 
formulations (adult and pediatric solutions and pediatric 
drops), of the same commercial brand, informed in the in-
sert that “diabetic patients should consult a physician” and 
“be carefully monitored” during treatment. One formula-
tion of an antitussive syrup with dropropizine warned that 
“diabetic patients should consider the sugar content pres-
ent in each formulation”. One of the commercial brands 
of loratadine decongestant syrup with pseudoephedrine 
did not mention its use by diabetic patients. 
Considering the four presentations with aspartame, 
a cefprozil suspension required “special attention with 
phenylketonuric patients”, informing that each 5ml of 
reconstituted suspension had 28mg of phenylalanine. A 
suspension of amoxicillin 600mg with clavulanate potas-
sium 42.9mg/ml recommended “careful with phenylke-
tonuric patients”, informing that each 5ml of medication 
had 7mg of phenylalanine.  The insert of a commercial 
brand of carbocystein (in granules - adult and pediatric 
formulations) omitted the information about its use by 
phenylketonuric patients. 
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Table 2. Preservatives found in the liquid pharmaceutical formulations 
analyzed (n=73).
Preservatives # of formulations (%)
Methylparaben 33 (45,2%)
Propylparaben 26 (35,6%)
Sodium benzoate 24 (32,8%)
Sodium metabisulfite 8 (11%)
Benzoic acid 4 (5,4%)
Hydroxyparabenzoate 4 (5,4%)
Potassium sorbate 2 (2,7%)
hydroxyparabenzoic acid 1 (1,3%)
Does not have 
preservatives**
2 (2,7%)
** Complex B polyvitamins in drops and acethylcystein in granules.
Dyes
Among the formulations analyzed, 32 (43.8%) did 
not have dyes. The dyes present in the other medications 
are listed on Table 3. Five products (6.8%) had more than 
one type of dye.
The inserts of a commercial brand of levodropropi-
zine (formulations: pediatric syrup and drops), acetylcys-
teine (drops) and acebrophylline (formulation: pediatric 
syrup) did not specify which was the red dye employed 
in the formulas. According to their customer care service, 
the first two presentations had the Bordeaux S red dye, 
and the latter had the food red. 
Tartrazine yellow was found in seven drug presenta-
tions (9.5% of the total): a) sodium dipirone in drops; b) 
paracetamol in drops; c) Benzydamine chloridrate in drops; 
d) pediatric decongestant liquid with bronpheniramine and 
phenylephrin; e) antitussive adult liquid with dropropizine, 
paracetamol and diphenydramine and pseudoephedrine 
chloridrates and f) antitussive – syrup and drops – based 
on levodropropizine. All the inserts included a warning 
about tartrazine, mandatory by Resolution RE # 572 from 
04/05/2002 of the Agência Nacional de Vigilância Sanitária 
(Brazilian Equivalent of the American FDA)12.
Aromatizers
Sixty one medications (83%) had the smell of fruits; 
six (8%), of tutti-frutti; four (5%) smelled of vanilla, four 
of caramel and 16 (22%) had other smells or essences 
(anise, cinnamon, gum, chocolate, egg, cassis, liquor, 
honey, menthol, rum, “forest smell”, “essence”, “half by 
half essence”, “sweet aroma” or “non-specified natural 
and artificial aromas).
Sixteen medications (21.9%) had two essences; 
seven (9.5%) had three essences.
Table 3. Dyes found in the pharmaceutical formulations analyzed 
(n=73).
Dyes # of formulations (%)
Dusk yellow (FD&C # 6) 11 (15%)
Tartrazine yellow (FD&C #5) 7 (9,5%)
Erythrosine 5 (6,8%)
Ponceau 4R red 4 (5,4%)
Caramel 3 (4,1%)
Red # 40 3 (4,1%)
Food red* 3 (4,1%)
Bordeaux S red* 2 (2,7%)
Quinoline yellow 2 (2,7%)
Yellow # 10 2 (2,7%)
Blue # 1 2 (2,7%)
Red # 10 1 (1,3%)
Iron oxide 1 (1,3%)
* Data not specified in four inserts, obtained through the manufacturer 
customer care center.
DISCUSSION
Kumar et al. (1993)5 analyzed the information on 
excipients present in the inserts of 102 drugs, and they 
saw that the data on preservatives, dyes and sweeteners 
present on the medications were omitted, in 35%, 20% 
and 10% of the inserts, respectively. In Brazil, Oliveira; 
Storpirtis (1999)1 assessed the inserts of 57 medicines and 
observed that only 40% had detailed information on the 
drug composition. In this paper we noticed that only one of 
the 73 inserts analyzed – of an over the counter medicine, 
for pediatric use, did not list the medicine excipients. 
Notwithstanding, sugar content was omitted in the 
inserts of 77% of the medicines that had the sweetener. It 
is very likely that we had two factors contributing to this 
fact: 1. the industrial secret around the product composi-
tion and 2. the voluntary character of the information, since 
quantifying inactive ingredients is not required by law6.
Inserts belonging to products sweetened by as-
partame did not mention the precautions to be taken by 
phenylketonuric patients, and four inserts (5.4%) did not 
specify the dye in their formulation. We had to call the 
customer care center of the drug companies in order to 
obtain the information. On the other hand, the inserts of 
all the seven medications which had the tartrazine yel-
low dye included the mandatory warning about the dye, 
complying with the legislation in effect12.
The omission and imprecision of some insert in-
formation about inactive ingredients expose susceptible 
individuals to the risk of having adverse reactions to some 
preservatives and dyes. Moreover, there may be complica-
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tions arising from the injudiciously use of drugs with sugar 
by diabetic patients, or of drugs sweetened by aspartame 
by phenylketonuric patients. For better safety, we believe 
it to be necessary to specify, in the drug insert, the type of 
dye used and, for the drugs that bear sugar or aspartame, 
stress the fact that diabetic and phenylketonuric patients, 
respectively, may or may not consume them. This is spe-
cially important in the inserts of over the counter medica-
tions, since we presuppose the consumer will use these 
drugs without the guidance of a physician. 
We observed some differences in the frequence of 
use of dyes in relation to the study by Kumar et al. (1993)5. 
In that sample, the most encountered dyes were # 40 red 
(41% of the medicines) and dusk yellow (26%). Most of 
the medications included in this study did not have dyes 
(48%) and those which had them were colored by dusk 
yellow (13%).
We highlight the fact that 13 commercial brands of 
antihistamine drugs analyzed by Kumar et al. (1993)5 had 
dyes, while the six formulations we assessed were color-
less. It is possible that in the last decade the pharmaceutical 
industry has decided to suppress the use of dyes in many 
formulations, in order to reduce adverse reactions. On 
the other hand, only one of 102 presentations assessed 
by Kumar et al. had tartrazine yellow (0.98%)5, while in 
our sample this dye was found in 9.5% of the medicines. 
Considering tartrazine adverse reaction risks, we believe it 
to be of benefit for the Brazilian pharmaceutical industry 
to replace it by natural dyes, such as sugar beet red18.
The most used preservatives in the medicines we 
assessed were methylparaben and propylparaben (45.2% 
and 35.6%, respectively). We highlight that only two for-
mulations (complex B polyvitamin drops and in granules 
acetylcysteine) did not have preservatives. 
The sweeteners we found more frequently were: su-
crose (sugar), in 53.4% of the medicines, sodium saccharin, 
in 38.3% and sorbitol in 36.9%. Thus, similar to Kulkarni et 
al. (1993)14, we also noticed that most of the formulations 
in syrup (69.2%) had sugar. It is important that physicians 
educate their patients – specially the pediatric population 
– to brush their teeth after ingesting sucrose-containing 
drugs, in order to prevent cavities. For chronic diseases that 
require long use of medicines, it is preferable to prescribe 
formulations in drops or artificially sweetned2.
The most found aromatizers in the pharmaceutical 
formulations studied were those resembling fruits (83%), 
among the large variety of essences used in the products. 
It is certain that these ingredients have a great psycho-
logical impact over consumers. Based on this we see 
that aromatizers are fundamental for the public to accept 
pharmaceutical products. 
CONCLUSIONS
Analyzing excipient information in the inserts of 
73 formulations of 35 medicines used orally, we noticed 
that:
1. One insert (1.3%) did not list the inactive ingre-
dients in the product.
2. The most commonly found preservatives were 
methylparaben (45.2%) and propylparaben (35.6%).
3. Drugs without dyes (43.8%) and those dyed by 
dusk yellow prevailed – yellow FD&C # 6 - (15%). Tartra-
zine (yellow FD&C # 5) was found in seven formulations 
(9.5%).
4. The most frequently used sweeteners were: su-
crose (sugar), in 53.4% of the medicines, sodium saccharin 
(38.3%) and sorbitol (36.9%).
5. The most commonly found aromatizers were the 
fruity ones (83%).
6. Thirty inserts of sugar loaded medications (77%) 
did not state the amount of sweetener present in the prod-
uct. Two of the four inserts of aspartame loaded medicines 
did not mention the precautions about their use by phe-
nylketonuric patients. Four inserts (5.4%) did not specify 
the type of dye used in the formulations.
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